Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 875-892-5 | CAS number: 1375799-59-9
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Skin sensitisation
Administrative data
- Endpoint:
- skin sensitisation: in chemico
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 02/09/2021 to 20/10/2021
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 021
- Report date:
- 2021
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 442C (In Chemico Skin Sensitisation: Direct Peptide Reactivity Assay (DPRA))
- Version / remarks:
- 26 June 2020
- GLP compliance:
- yes (incl. QA statement)
- Type of study:
- direct peptide reactivity assay (DPRA)
Test material
- Reference substance name:
- Sodium 1-[6-(morpholin-4-yl)pyrimidin-4-yl]-4-(1H-1,2,3-triazol-1-yl)-1H-pyrazol-5-olate
- EC Number:
- 875-892-5
- Cas Number:
- 1375799-59-9
- Molecular formula:
- C13 H14 N8 O2 . Na
- IUPAC Name:
- Sodium 1-[6-(morpholin-4-yl)pyrimidin-4-yl]-4-(1H-1,2,3-triazol-1-yl)-1H-pyrazol-5-olate
Constituent 1
In chemico test system
- Details of test system:
- cysteine peptide, (Ac-RFAACAA-COOH)
- lysine peptide (Ac-RFAAKAACOOH)
- Details on the study design:
- PREPARATION OF TEST SOLUTIONS
- Preparation of the peptide/derivative stock solutions: Stock solutions of each peptide at concentrations of 0.667 mM were prepared by dissolution of pre-weighed aliquots of the appropriate peptide in approximately 20 mL aliquots of the appropriate buffer solution (cysteine in 100 mM phosphate buffer pH 7.5, lysine in 100 mM ammonium acetate buffer pH 10.2).
- Preparation of the test chemical solutions
- Preparation of the positive controls, reference controls and co-elution controls:
Preparation of positive control and cysteine peptide depletion samples and co-elution controls:
Triplicate solutions each of the positive control and test item stock solutions were diluted
with the cysteine peptide stock solution to prepare solutions containing 500 µM cysteine and
5 mM of trans-cinnamaldehyde or 5 mM ofthe test item. For the co-elution control, buffer
solution was used instead of the cysteine stock solution.
Preparation of positive control and lysine peptide depletion samples and co-elution controls:
Triplicate solutions each of the positive control and test item stock solutions were diluted
with the lysine peptide stock solution to prepare solutions containing 500 µM lysine and
25 mM of cinnamaldehyde or 25 mM of the test item. For the co-elution control, buffer
solution was used instead of the lysine stock solution.
INCUBATION
- Incubation conditions: 500 uM cysteine and lysine peptide solutions were incubated in glass autosampler vials with 5 mM or 25 mM of the test item, respectively. The reaction solutions were incubated in the dark at 22.5-30 °C for 24 ± 2 h prior to initiation ofthe analysis run.
- Precipitation noted
PREPARATION OF THE HPLC
- Standard calibration curve for both Cys and Lys: Calibration standards of both peptides were prepared in a solution of 20% acetonitrile:buffer using phosphate buffer (pH 7.5) for the cysteine peptide and ammonium acetate buffer (pH 10.2) for the lysine peptide. The following calibration solutions were prepared from the peptide stock solution of each peptide at concentrations of 0.0167 mM, 0.0334 mM, 0.0667 mM, 0.133 mM, 0.267 mM and 0.534 mM. A blank ofthe dilution buffer was also included in the standard calibration curve for both peptides. The blank is 25% acteonitrile:buffer solution with phosphate buffer (pH 7 .5) for the cysteine peptide and with ammonium acetate buffer (pH 10.2) for the lysine peptide without peptide.
- Verification of the suitability of the HPLC for test chemical and control substances:
Reference control A: For the verification ofthe HPLC system suitability (samples containing 0.5 mM peptide dissolved in the appropriate peptide buffer and acetonitrile). n=1 with 3-fold injections.
Reference control B: For the stability ofthe reference controls over time (samples containing 0.5 mM peptide dissolved in the appropriate peptide buffer and acetonitrile). n=6.
Reference control C1: Peptide stability control for the solvent used to dissolve the test item
and the positive control (samples containing 0.5 mM peptide dissolved in the appropriate peptide buffer and acetonitrile). n=3.
Reference control C2: Peptide stability control for the solvent used to dissolve the test item
(samples containing only 0.5 mM peptide dissolved in the appropriate peptide buffer and deionized water. n=3.
Co-elution control: Sample prepared of the respective peptide buffer and the test item or
the positive control without peptide. n=1, each.
DATA EVALUATION
- Cys and Lys peptide detection wavelength: 220 nm and 258 nm
The concentration of cysteine or lysine peptide was photometrically determined at 220 nm in
each sample by measuring the peak area (area under the cuiye, AUC) ofthe appropriate
peaks and by calculating the concentration ofpeptide using the linear calibration curve
derived from the standards.
The peptide depletion of a sample was calculated as follows:
Peptidpeak area in replicate injection
Percent peptide depletion = [1 - ------------------------------------------------------------------------] x 100
Mean peptide peak area in reference control C - Vehicle / solvent:
- water
- Positive control:
- cinnamic aldehyde
Results and discussion
In vitro / in chemico
Resultsopen allclose all
- Key result
- Group:
- test chemical
- Run / experiment:
- mean
- Parameter:
- lysine depletion
- Vehicle controls validity:
- valid
- Negative controls validity:
- not valid
- Positive controls validity:
- valid
- Remarks on result:
- other: co-elution peak with lysine peptide buffer
- Key result
- Group:
- test chemical
- Run / experiment:
- mean
- Parameter:
- cysteine depletion
- Value:
- 42.7 %
- At concentration:
- 5 mM
- Vehicle controls validity:
- valid
- Negative controls validity:
- valid
- Positive controls validity:
- valid
- Outcome of the prediction model:
- moderate reactivity [in chemico]
- Other effects / acceptance of results:
- OTHER EFFECTS:
- Visible damage on test system: No
ACCEPTANCE OF RESULTS:
- Acceptance criteria met for positive control:Yes: 60.8-100% for the cysteine peptide: 74.5%
- Acceptance criteria met for reference controls A to C:Yes:
A: 495 µM(CV 0.853%, n=3)
B: 490 µM (CV 0.880%,n=6)
C1: 491 µM 8CV 0.674%, n=3)
C2: 505 µM (CV 0.491%, n=3)
SD = 2.55 (n=3)
- Acceptance criteria met for co-elution controls (Lysine and Cysteine): only for Cysteine
- Acceptance criteria met for variability between replicate measurements: Yes: <14.9 percent points for the cysteine depletion: 2.55 (test item; 1.32 (positive control)
- Range of historical values if different from the ones specified in the test guideline: Please refer to 'any other information on results incl. tables'
Any other information on results incl. tables
Historical Control Data for the positive control | ||||
| Cysteine peptide concentration (µM)1 | Cysteine depletion % | Lysine peptide concentration (µM)² | Lysine depletion % |
Mean | 134 | 72.8 | 254 | 49.2 |
SD | 14.9 | 3.00 | 45.9 | 9.27 |
CV (%) | 11.1 | 4.12 | 18.0 | 18.9 |
n | 57 | 57 | 54 | 54 |
1 Samples prepared at a concentration of 500 µM (376 µg/mL) 2 Samples prepared at a concentration of 500 µM (388 µg/mL] | ||||
| ||||
Historical control data reference control A | ||||
| Cysteine peptide concentration (µM)1 | Cysteine peptide Rt (min) | Lysine peptide concentration (µM)² | Lysine peptide Rt (min) |
Mean | 505 | 11.5 | 508 | 8.54 |
SD | 9.57 | 0.0526 | 13.8 | 0.0692 |
CV (%) | 1.90 | 0.456 | 2.71 | 0.810 |
n | 57 | 57 | 54 | 57 |
Rt Retention time 1 Samples prepared at a concentration of 500 µM (376 µg/mL) 2 Samples prepared at a concentration of 500 µM (388 µg/mL) | ||||
| ||||
Historical Control Data Reference Control B | ||||
| Cysteine peptide concentration (µM)1 | Cysteine peptide Rt (min) | Lysine peptide concentration (µM)² | Lysine peptide Rt (min) |
Mean | 493 | 11.5 | 500 | 8.55 |
SD | 11.9 | 0.0529 | 14.0 | 0.0955 |
CV (%) | 2.43 | 0.459 | 2.79 | 1.12 |
n | 114 | 114 | 108 | 114 |
Rt Retention time 1 Samples prepared at a concentration of 500 µM (376 µg/mL) 2 Samples prepared at a concentration of 500 µM (388 µg/mL) |
Individual achieved peptide depletion values in the presence of the positive control and the test item
Sample | Cysteine peptide depletion [%] | Mean Cysteine depletion [%] | SD Cysteine (p.p.) | Lysine peptide depletion [%] | Mean Lysine depletion [%] | SD Lysine (p.p.) |
Positive Control | 73.01 | 74.5 | 1.32 | 62.0² | 61.9 | 0.690 |
74.71 | 61.2² | |||||
75.61 | 62.6² | |||||
Test item | 39.9³ | 42.7 | 2.55 | 0.004 | 0.00 | 0.00 |
43.6³ | 0.004 | |||||
44.7³ | 0.004 |
SD Standard deviation
p.p. percent points
1 Calculated against a cysteine mean reference control (C1) area of 3332805 (n=3)
2 Calculated against a lysine mean reference control (C1) area of 2813285 (n=3)
3 Calculated against a cysteine mean reference control (C2) area of 3424662 (n=3)
4 Calculated against a lysine mean reference control (C2) area of 2753807 (n=3)
Acceptance criteria of each peptide
| Peptide | Standard linearity | Positive control depletion (p.p.) | Reference controls (mean peptide concentration/coefficient of variation) | SD test item depletion (p.p.) |
Acceptance criteria | Cysteine | r² > 0.99 | 60.8 – 100 (SD < 14.9) | 450 - 550 µM (CV < 15%) | SD < 14.9 |
| Lysine | r² > 0.99 | 40.2 – 69.0 (SD < 11.6) | 450 - 550 µM (CV < 15%) | SD < 11.6 |
Achieved results | Cysteine | r² > 0.9998 | 74.5 (SD, 1.32, n=3) | A: 495 µM (CV 0.853%, n=3) B: 490 µM (CV 0.880%, n=6) C1: 491 µM (CV 0.674%, n=3) C2: 505 µM (CV 0.491%, N=3) | SD 2.55 (n=3) |
| Lysine | r² > 0.9997 | 61.9 (SD, 0.690, N=3) | A: 503 µM (CV 0.390%, n=3) B: 511 µM (CV 1.42%, n=6) C1: 507 µM (CV1.67%, n=3) C2: 496 µM (CV 0.362%, n=3) | SD 0.00 (n=3) |
SD Standard deviation p.p. percent points |
Applicant's summary and conclusion
- Interpretation of results:
- other: This DPRA can be used as part of a testing battery based on the OECD adverse Outcome Pathway (AOP) for the assessment of the skin sensitisation potential of chemicals.
- Conclusions:
- Solutions of Molidustat were analyzed by the DPRA method in both the cysteine and lysine containing synthetic peptides. A co-elution peak was obseryed in the lysine assay.
Since co-elution of the test item was observed with the lysine peptide the prediction was one only with the cysteine peptide. With moderate mean depletion ofthe cysteine peptide (42.7%) in the presence of the test item, Molidustat is therefore predicted by DPRA as positive and to be a potential skin sensitizer based on this assay.
Based on the results a score of 2 is applied according to OECD TG 497 (June 2021) - Executive summary:
In an in chemico skin sensitisation study performed according to OECD test guideline 442C (Direct Peptide Reactivity Assay) the reactivity of the test item Molidustat was evaluated by monitoring peptide depletion following a 24-hour contact between the test item and synthetic cysteine and lysine peptides.
The test item was dissolved at 100 mM in a 1:1 mixture of water:acetonitrile. The positive control was cinnamaldehyde, and for each peptide, the analytical batch included co-elution control samples and three reference control samples.
Reactivity (%depletion) was determined following 24-hour contact between test item and peptide in acetonitrile at the ratios 1:10 cysteine:test item and 1:50 lysine:test item by liquid chromatography with UV-detection.
Peptide reactivity was reported as percent depletion based on the peptide peak area of the replicate injection and the mean peptide peak area in the two relevant reference control C samples for Cysteine. Since co-elution of the test item was observed with the lysine peptide the prediction was done only with the cysteine peptide. The acceptance criteria for the calibration curve samples, the reference and positive controls as well as for the study samples were satisfied and thus demonstrated the validity of the study.
Analysis of the chromatograms of the co-elution samples indicated that the test item did not co-elute with the cysteine peptides. As a result, the mean percent depletion values were calculated for the cysteine peptide. For the cysteine peptide, the mean depletion value was 42.7%.
Since the mean of the percent cysteine depletionwas greater than 23.09%, the test item was considered to have moderate peptide reactivity. Therefore, the DPRA prediction would be considered as positive and the test item may have the potential to cause skin sensitisation.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.